Back to mobile site

Morgan Stanley Reiterates Overweight Rating on Axsome Therapeutics (AXSM)

August 23, 2024 11:30 AM EDT Send to a Friend
Morgan Stanley analyst Vikram Purohit reiterated an Overweight rating and $115.00 price target on Axsome Therapeutics (NASDAQ: AXSM)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login